

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

KATSIKI 1



Section 1. Identifying Info	ormation							
Given Name (First Name)     NIKI		Surname (Last Name)     3. Date						
4. Are you the corresponding author?	<b>√</b> Yes [							
5. Manuscript Title DIABETES AND CAROTID ARTERY DISEASE: a narrative review								
6. Manuscript Identifying Number (if yo ATM-19-3633	u know it)							
Section 2. The Week Under								
The Work Unde	r Consideratio	n for Publication						
Did you or your institution <b>at any time</b> is any aspect of the submitted work (include statistical analysis, etc.)?  Are there any relevant conflicts of in	ding but not limited	d to grants, data monii			tc.) for			
Section 3. Relevant finance	ial activities o	utside the submit	ted work.					
Place a check in the appropriate box of compensation) with entities as de clicking the "Add +" box. You should Are there any relevant conflicts of in If yes, please fill out the appropriate	escribed in the instructions in the instruction in	structions. Use one linips that were <b>prese</b>	ne for each enti	ity; add as many lines as you nee	d by			
Name of Entity		rsonal Non-Finan		Comments				
Astra Zeneca		<b>✓</b>		peaker fees and travel expenses				
Bausch Health		✓		peaker fees and travel expenses	1			
Boehringer Ingelheim		<b>✓</b>	S	peaker fees and travel expenses	1			
Elpen		<b>✓</b>	S	peaker fees and travel expenses				
MSD		<b>✓</b>	S	peaker fees and travel expenses				
Лylan		<b>✓</b>	S	peaker fees and travel expenses				
Novo Nordisk		<b>✓</b>	S	peaker fees and travel expenses				
Sanofi		<b>✓</b>	S	peaker fees and travel expenses				

KATSIKI 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Servier		<b>✓</b>			Speaker fees and travel expenses
Section 4. Intellectual Brancut					
Intellectual Propert	y Pate	ents & Co	pyrights		
Do you have any patents, whether plann	ed, pendi	ng or issue	ed, broadly releva	ant to the	work? ☐ Yes ✓ No
Section 5. Relationships not c	overed a	above			
Are there other relationships or activities				influence	d, or that give the appearance of
potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/cond	itions/cir	cumstance	es are present (ex	plain belo	ow):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6. Disclosure Statemen	nt				
Based on the above disclosures, this form below.	n will auto	omatically	generate a disclo	sure state	ment, which will appear in the box
NK has given talks, attended confe Health, Boehringer Ingelheim, Elp					

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

KATSIKI 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

MIKHAILIDIS 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fi	rst Name)	2. Surnan	ne (Last Name) IDIS		3. Date 19-March-2020		
4. Are you the cor	responding author?	Yes	✓ No	-	Corresponding Author's Name NIKI KATSIKI		
5. Manuscript Title DIABETES AND C	AROTID ARTERY DISEA	SE: a narra	tive review				
6. Manuscript Ider ATM-19-3633	ntifying Number (if you kn	ow it)					
Cartina							
Section 2.	The Work Under Co	onsiderat	ion for Publ	ication			
any aspect of the s statistical analysis,	ubmitted work (including	but not lim	ited to grants, o		•	ent, commercial, private foundation, etc.) for udy design, manuscript preparation,	
	out the appropriate info be removed by pressing		•	ave more tha	n one enti	ity press the "ADD" button to add a row.	
Name of Institut	ion/Company	Grant?		on-Financial Support <mark>?</mark>	Other?	Comments	
Amgen			✓			Speaker fees and travel expenses	
Novo Nordisk					<b>✓</b>	Advisory Board member	
	1						
Section 3.	Relevant financial	activities	outside the	submitted	work.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .							
Are there any rel	evant conflicts of intere	est?	'es ✓ No				
	l						
Section 4.	Intellectual Proper	ty Pate	nts & Copyr	ights			
Do you have any	patents, whether plan	ned, pendi	ng or issued, l	oroadly relev	ant to the	work? Yes V No	

MIKHAILIDIS 2



Section 5.	Deletional in a set accessed above			
	Relationships not covered above			
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?			
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):			
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest			
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement			
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box			
<b>DPM</b> has give and Libytec.	en talks, acted as a consultant or attended conferences sponsored by Amgen, Novo Nordisk			

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

MIKHAILIDIS 3